N/A N=54 Proton Radiation for Chordomas and Chondrosarcomas
Chordomas · Chondrosarcomas
Primary: Feasibility of Proton RT for Chordomas and Chondrosarcomas — 3.7; 1.9 percentage of patients did not meet this
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 BN Brachyury and Radiation in Chordoma
Chordoma
Primary: Objective Response Rate (ORR) — 7.7 percentage of subjects with OR
Phase 2 N=24 QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
Chordoma
Primary: Overall Response Rate — 1; 1 Participants
N/A N=87 Chordate System Prophylactic Migraine Clinical Investigation
Migraine
Primary: Change From Baseline in Number of Migraine Days Per Four Weeks During the Three Months Post Treatment Investigation Duration — -1.5; -1.3 Migraine days/four weeks…
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Phase 2 N=47 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Chondrosarcoma · Metastatic Chondrosarcoma
Primary: Disease Control at Week 16 — 43 Percentage of CR+PR+SD
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 2 N=34 Monthly SOM230C for Recurrent or Progressive Meningioma
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
N/A N=36 Stereotactic Body Radiotherapy for Spine Tumors
Spinal Metastases · Vertebral Metastases · Benign Spinal Tumors
Primary: Initial Symptom Control — 3; 28; 3; 27 Participants
Phase 2 N=24 Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Locally Advanced Basal Cell Carcinoma · Skin Cancer · Cutaneous Malignancy
Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage
Phase 2 N=17 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
Phase 3 N=30 Effects of CHONDRON (Autologous Chondrocytes) With Ankle Cartilage Defect
Articular Cartilage Defects of Ankle Joint
Primary: Average Change From Baseline in American Orthopedic Foot and Ankle Society(AOFAS) at 12 Months Post-surgery — 16.93 scores
N/A N=1 Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
Adenoid Cystic Carcinoma
Primary: Number of Participants With Disease Progression — 1 Participants
N/A N=162 Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia
Arnold-Chiari Malformation, Type 1 · Chiari Malformation Type I · Type I Arnold-Chiari Malformation
Primary: The Number of Participants With Surgical Complications — 8; 10 Participants
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants